Login / Signup

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Svenja NöltingJakob RentschHelma FreitagKatharina DetjenFranziska BriestMarkus MöbsVictoria WeissmannBritta SiegmundChristoph J AuernhammerElke Tatjana Aristizabal PradaMichael LausekerAshley GrossmanSamantha ExnerChristian FischerCarsten GrötzingerJörg SchraderPatricia Grabowskinull null
Published in: PloS one (2017)
Our results suggest that the agent BYL719 could be a novel therapeutic approach to the treatment of NETs that may sensitize NET cells to somatostatin analogs, and that if there is resistance to its action this may be overcome by combination with everolimus.
Keyphrases
  • neuroendocrine tumors
  • induced apoptosis
  • cell cycle arrest
  • molecular docking
  • cell death
  • oxidative stress
  • combination therapy
  • cell proliferation
  • signaling pathway
  • replacement therapy
  • pi k akt